TOBI podhaler (Tobramycin)
tobramycin 28 mg powder for inhalation, 224 capsules · INHALATION_BY_MOUTH · PBS code 10066T
STREAMLINEDWhat it costs
AU$2282.85 PBS-determined price per 224 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2014-04-01.
- • Repeats: 0.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Proven Pseudomonas aeruginosa infection
Initial treatment
Patient must have cystic fibrosis; AND
Patient must have been assessed for bronchial hyperresponsiveness as per the TGA-approved Product Information, with a negative test result; AND
Patient must be participating in a four week trial of tobramycin inhalation powder and will be assessed for ability to tolerate the dry powder formulation in order to qualify for continued PBS-subsidised therapy. The trial commencement date must be documented in the patient's medical records; AND
Patient must be 6 years of age or older; AND
Must be treated by a medical practitioner; or
Must be treated by a nurse practitioner where patient care is being shared with a medical practitioner.
Sponsor: Viatris Pty Ltd ABN 29 601 608 771
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.